Bayer, Mammoth Biosciences to team up for novel gene editing tech
Category: #headlines  | By Nikita Chaurasia  | Date: 2022-01-11 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Bayer, Mammoth Biosciences to team up for novel gene editing tech

Pharmaceutical and life sciences company Bayer AG has reportedly entered into a strategic collaboration and option agreement with Mammoth Biosciences Inc., a company that is harnessing nature's diversity to power novel CRISPR products, to use Mammoth’s CRISPR systems for creating in vivo gene-editing therapies.

Developed by Mammoth Biosciences, the revolutionary gene-editing technology is both a crucial enabler and a stand-alone therapeutic approach. It will help Bayer accelerate the development of breakthrough therapies for patients while also bolstering the company's newly developed cell and gene therapy platform. As per the agreement, the two businesses will begin their collaboration by focusing on liver-targeted disorders.

Notably, the development of cell and gene therapies is the next major step in the drug development field. They may be capable of permanently curing diseases with a one-time treatment by addressing the fundamental cause of disorders.

When used outside the living body (ex vivo), gene editing is a crucial enabler for cell treatments, and when used inside the living body, it enables therapeutic targeting of a variety of genetic illnesses with a high unmet medical need (in vivo).

The exclusive toolset of ultra-small Cas enzymes developed by Mammoth Biosciences, including Cas14 and Cas, enables high-fidelity gene editing to be paired with targeted systemic administration. Bayer now has access to this innovative gene-editing technology, which has the potential for increased in vivo applicability owing to the ultra-compact size of these innovative CRISPR systems.

Mammoth Biosciences will be paid around USD 40 million in advance and will be eligible for target option exercise fees and potential future payments in the amount of more than USD 1 billion after certain research & development, as well as commercial landmarks are achieved across 5 preselected in vivo indications, with a primary emphasis on liver-targeted diseases, as per the terms of the agreement.

Bayer will also provide research funds and tiered royalties up to a low double-digit percentage of net sales. On a nonexclusive basis, the companies are also looking to work on ex vivo projects.

Source Credits: https://www.businesswire.com/news/home/20220109005059/en/Bayer-and-Mammoth-Biosciences-to-Collaborate-on-Novel-Gene-Editing-Technology

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

McKinsey commences job cuts focused on non-client serving teams

McKinsey commences job cuts focused on non-client serving teams

By Nikita Chaurasia

McKinsey and Co. a consulting giant entity has decided to start cutting jobs in one of the biggest rounds of layoffs for the company. This is likely to eliminate the jobs of about 2000 employees from work. The layoffs will be focused on support st...

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...